Evidence map›Paper›PMID 41718400›Full record

ArticleAntibodies (Basel, Switzerland)2026

Comparative In Vitro Evaluation of Anti-HIV Immunotoxin, Antibody-Drug Conjugate, and Radioimmunoconjugate Targeted by the Same Antibody.

Anne-Sophie Kuhlmann, Tami Peters, Donald K Hamlin, Yawen Li, Xinyi Wang, Megan Stackhouse, Frances M Cole, Jasmin Martinez-Reyes, Brenda M Sandmaier, Hans-Peter Kiem and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibodies (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anne-Sophie KuhlmannTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0007-3017-0448
Tami PetersDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, MT 59717, USA.
Donald K HamlinDepartment of Radiation Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Yawen LiDepartment of Radiation Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Xinyi WangTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-9066-792X
Megan StackhouseDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, MT 59717, USA.
Frances M ColeDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, MT 59717, USA.
Jasmin Martinez-ReyesTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Brenda M SandmaierTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-9767-9739
Hans-Peter KiemTranslational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
D Scott WilburDepartment of Radiation Oncology, School of Medicine, University of Washington, Seattle, WA 98195, USA.
Robert D HarringtonDepartment of Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA.
Seth H PincusDepartment of Chemistry & Biochemistry, Montana State University, Bozeman, MT 59717, USA.ORCID 0000-0003-1622-4386

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
National Institute of Allergy and Infectious Diseases R01AI136758NCI NIH HHS P30 CA015704
6 · The paper itself

Abstract

backgroundWe are developing cytotoxic immunoconjugates (CICs) to eliminate HIV-infected cells. We investigated the efficacy and kinetics of killing by different forms of CICs targeted by the same monoclonal antibody (mAb), an immunotoxin (IT), antibody-drug conjugate (ADC), and radioimmunoconjugate (RIC).

methodsWe compared in vitro effects of CICs made by conjugating anti-gp41 mAb 7B2 to deglycosylated ricin A chain (7B2-dgA), the anthracycline derivative PNU-159682 (7B2-PNU), or the α-emitting isotope actinium-225 (7B2-

results7B2-dgA and 7B2-

conclusionsAn IT, ADC, and RIC showed substantial differences in the degree of specific toxicity, kinetics, and mechanisms of killing. The results of this side-by-side comparison have implications for the development of CICs to treat HIV, as well as other conditions.

Indexed as

antibody-drug conjugatecytotoxic immunoconjugategp160gp41HIV envelope proteinHIV reservoir eradicationimmunotherapyimmunotoxinmetabolomicsmonoclonal antibodyradioimmunoconjugateRNAseq

Identifiers

PMID41718400
PMCPMC12921964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.